Precision Targeting of Mutant PI3Kα

Cancer Discov. 2024 Feb 8;14(2):204-207. doi: 10.1158/2159-8290.CD-23-1392.

Abstract

PIK3CA, which encodes the p110α catalytic subunit of PI 3-kinase alpha (PI3Kα), is one of the most frequently genetically activated kinases in solid tumors. In two back-to-back papers, Varkaris and colleagues report on the development of a novel allosteric PI3Kα-mutant-selective inhibitor and early clinical experience with this compound. See related article by Varkaris et al., p. 227 (6) . See related article by Varkaris et al., p. 240 (5) .

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Class I Phosphatidylinositol 3-Kinases / genetics
  • Humans
  • Mutation
  • Phosphatidylinositol 3-Kinases* / genetics
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Phosphatidylinositol 3-Kinases
  • Phosphoinositide-3 Kinase Inhibitors
  • Class I Phosphatidylinositol 3-Kinases
  • Antineoplastic Agents
  • Protein Kinase Inhibitors